NCT04640974 - Study of Cingal® for Symptomatic Relief of Osteoarthritis of Ankle Joint | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 14, 2021

Primary Completion Date

September 24, 2021

Study Completion Date

September 24, 2021

Conditions

Osteoarthritis, Ankle

Interventions

DEVICE

Cingal

Single injection into the ankle joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH).

Trial Locations (4)

401 13

Krajská zdravotní, a.s. - Masarykova nemocnice Ústí nad Labem, o.z., Ústí nad Labem

44-100

NZOZ MEDI-SPATZ M.Spatz, Gliwice

90-038

SPORTO sp. z o.o, Lodz

87-100

Przychodnia Rodzinna na Sadowej, Torun